» Articles » PMID: 24133591

MAPK/ERK Signal Pathway Involved Expression of COX-2 and VEGF by IL-1β Induced in Human Endometriosis Stromal Cells in Vitro

Overview
Specialty Pathology
Date 2013 Oct 18
PMID 24133591
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Now there are more and more evidences that Cyclooxygenase-2 (COX-2) plays an important role in angiogenesis of endometriosis (EMs). Vascular endothelial growth factor (VEGF) has a potent angiogenic activity. However, it is worth studying about the regulating mechanism of COX-2/COX-1 and VEGF in the development of human endometriosis in vitro. The current study was designed to investigate the effect of 4 cytokines on COX-2/COX-1 expression and the effect of IL-1β on VEGF release in human endometriosis stromal cells (ESC), and to explore the related signaling pathways involved in vitro.

Methods: Isolation, culture and identification of ESC. Cells were treated with 4 cytokines, and the inhibitor mitogen-activated protein-Erk (MEK) and the inhibitor p38 mitogen-activated protein kinase (MAPK) prior to adding cytokine IL-1β. COX-2 protein expression was measured by western blot and VEGF secretion was determined by ELISA.

Results: Among four kinds of cytokines, IL-1β treatment increased COX-2 protein expression and VEGF release in three ESC, and TNF-α had the same effect on COX-2 protein level as IL-1β only in ectopic and eutopic ESC, and MCSF had only slight effect on ectopic ESC. In contrast, cytokines had no effect on COX-1 expression. We also demonstrated that MAPK reduced the synthesis of COX-2 by IL-1β induced. COX-2 inhibitor reduced VEGF release by IL-1β induced.

Conclusions: i) In human ESC in vitro, IL-1β up-regulated the COX-2 expression through the activation of p38 MAPK pathway, and not to COX-1. ii) Up-regulation of VEGF level by IL-1β treatment was found in human endometriosis stromal cell and COX-2 inhibitor was involved in this process.

Citing Articles

The long road of drug development for endometriosis - Pains, gains, and hopes.

Liao Z, Monsivais D, Matzuk M J Control Release. 2024; 376:429-440.

PMID: 39427778 PMC: 11884332. DOI: 10.1016/j.jconrel.2024.10.036.


Anti-Inflammatory and Anti-Adipocyte Dysfunction Effects of Latex and Root Extracts.

Karinchai J, Buacheen P, Rodthayoy D, Yodweerapong T, Imsumran A, Wongnoppavich A Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543073 PMC: 10974239. DOI: 10.3390/ph17030287.


Novel oxicam nonsteroidal compound XK01 attenuates inflammation by suppressing the NF-κB and MAPK pathway in RAW264.7 macrophages.

Wang J, Tan J, Hu Q, Mao S, Chen H, Luo W Heliyon. 2024; 10(2):e24004.

PMID: 38312593 PMC: 10835217. DOI: 10.1016/j.heliyon.2024.e24004.


The Role of Quercetin for the Treatment of Endometriosis and Endometrial Cancer: A Comprehensive Review.

Chaichian S, Chaichian S, Nikfar B, Bidgoli S, Moazzami B Curr Med Chem. 2023; 32(1):74-86.

PMID: 37861023 DOI: 10.2174/0109298673269733230921092509.


Digestive system deep infiltrating endometriosis: What do we know.

Yin W, Li X, Liu P, Li Y, Liu J, Yu S J Cell Mol Med. 2023; 27(23):3649-3661.

PMID: 37632165 PMC: 10718155. DOI: 10.1111/jcmm.17921.


References
1.
Liu Q, Huang F, Wang H, Zou Y . [Effect of GnRH-II on VEGF secreted by stromal cells from endometrium of endometriosis]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009; 34(9):926-32. View

2.
Aoki T, Nagakawa Y, Tsuchida A, Kasuya K, Kitamura K, Inoue K . Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumors. Oncol Rep. 2002; 9(4):761-5. View

3.
Griffith J, Rodgers A, Schenken R . Reviews: in vitro models to study the pathogenesis of endometriosis. Reprod Sci. 2009; 17(1):5-12. DOI: 10.1177/1933719109338221. View

4.
Hull M, Prentice A, Wang D, Butt R, Phillips S, Smith S . Nimesulide, a COX-2 inhibitor, does not reduce lesion size or number in a nude mouse model of endometriosis. Hum Reprod. 2004; 20(2):350-8. DOI: 10.1093/humrep/deh611. View

5.
Peng Z, Wan D, Li L, Chen G, Lu Z, Wu X . Expression of COX-2, MMP-2 and VEGF in stage II and III colorectal cancer and the clinical significance. Hepatogastroenterology. 2011; 58(106):369-76. View